Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 5/20 | 0.32 |
| ▸ | MC5R | P33032 | 5/20 | 0.32 |
| ▸ | MC3R | P41968 | 5/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4162508 | 0.90 | PKM (0.35) | PKMHTR1DHTR1BMC4RMC5R | |
| SCHEMBL4161009 | 0.89 | GPR17 (0.36) | GPR17GRIN1S1PR1GAA | |
| SCHEMBL4171968 | 0.89 | PKM (0.35) | PKMHTR1DHTR1BMC4RMC5R | |
| SCHEMBL4166910 | 0.84 | KDM4E (0.39) | HTR1DHTR1BMC4RMC5RMC3R | |
| SCHEMBL3244399 | 0.83 | GAA (0.41) | PKMGAA | |
| SCHEMBL4159472 | 0.80 | HTR1D (0.37) | HTR1DHTR1BGAAUSP2LMNA | |
| Hydrochloric Acid SCHEMBL4161185 | 0.79 | GPR17 (0.32) | GPR17MC4RMC5RMC3R | |
| SCHEMBL4157860 | 0.79 | MAPT (0.37) | HTR1DHTR1BGAAUSP2LMNA | |
| Hydrochloric Acid SCHEMBL4161189 | 0.79 | GPR17 (0.32) | GPR17MC4RMC5RMC3R | |
| Butyric Acid SCHEMBL4171746 | 0.79 | PKM (0.37) | PKMGRIN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | PKM 276/4885GPR17 2461/4885HTR1D 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.